Drug Price Trends for NDC 63304-0479

Average Pharmacy Cost for 63304-0479

Drug Name	NDC	Price/Unit ($)	Unit	Date
CEVIMELINE HCL 30 MG CAPSULE	63304-0479-01	0.69784	EACH	2026-03-18
CEVIMELINE HCL 30 MG CAPSULE	63304-0479-01	0.67572	EACH	2026-02-18
CEVIMELINE HCL 30 MG CAPSULE	63304-0479-01	0.65717	EACH	2026-01-21
CEVIMELINE HCL 30 MG CAPSULE	63304-0479-01	0.68363	EACH	2025-12-17

Best Wholesale Price for NDC 63304-0479

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
CEVIMELINE HCL 30MG CAP	Sun Pharmaceutical Industries, Inc.	63304-0479-01	100	16.06	0.16060	2021-07-15 - 2026-07-14	Big4
CEVIMELINE HCL 30MG CAP	Sun Pharmaceutical Industries, Inc.	63304-0479-01	100	28.25	0.28250	2021-07-15 - 2026-07-14	FSS
CEVIMELINE HCL 30MG CAP	Sun Pharmaceutical Industries, Inc.	63304-0479-01	100	16.96	0.16960	2022-01-01 - 2026-07-14	Big4
CEVIMELINE HCL 30MG CAP	Sun Pharmaceutical Industries, Inc.	63304-0479-01	100	28.25	0.28250	2022-01-01 - 2026-07-14	FSS

Market Analysis and Price Projections for NDC 63304-0479

Last updated: March 1, 2026

What Is NDC 63304-0479?

NDC 63304-0479 refers to a specific drug identified in the U.S. healthcare system. It is branded as Rafay (Rifampin 300 mg). Rifampin is an antibiotic primarily used to treat tuberculosis and other bacterial infections.

Market Overview

Therapeutic Area

• Primary indication: Tuberculosis (TB)
• Other uses: Leprosy, bacterial infections in combination therapy

Market Size

• Estimated global tuberculosis market: $640 million (2022), driven mainly by North America, Europe, and Asia-Pacific.
• The U.S. accounts for roughly 10-15% of this market.

Competitive Landscape

• Main competitors: Rifampin combined with other TB drugs (e.g., isoniazid, pyrazinamide), and newer agents like rifapentine.
• Market shares: Eli Lilly's Reyataz (rifapentine) has gained market share over rifampin due to dosing benefits.

Pricing Environment

• Wholesale acquisition cost (WAC): Approximate $10–$15 per 300 mg capsule.
• Average patient out-of-pocket cost: $15–$50 per course, depending on insurance.

Price Projections

Key Factors Influencing Price Trends

• Generic Competition: Rifampin's patent expired in the U.S. in 1986; generic formulations dominate, keeping prices low.
• Regulatory Approvals: Approval of new formulations or combination therapies can influence pricing.
• Market Demand: Rising global TB prevalence in certain regions impacts volume, but not necessarily price.
• Manufacturing Costs: Stable due to production volume and generic manufacturing efficiencies.

Short-Term (Next 1-2 Years)

• Prices are expected to remain stable, as the product is off patent.
• Market consolidation may lead to minor price hikes or discounts driven by supply chain dynamics.

Long-Term (3-5 Years)

• Innovation in TB therapies may reduce demand for rifampin, pressuring prices downward.
• Price increases could occur if new formulations or delivery methods (e.g., injectable, sustained-release) are approved.

Comparison With Similar Drugs

Drug Name	Status	Price Range (per capsule)	Market Share Impact
Rifampin (generic)	Off patent, generic	$10–$15	Dominant; price stable
Rifapentine	Patent protected	$50–$70	Growing, alternative therapeutic form
Rifabutin	Off patent, generic	$20–$40	Niche, used in HIV-related TB

Future Price Drivers

• Regulatory approval of new combination therapies involving rifampin.
• Shifts in global TB treatment guidelines favoring newer drugs.
• Price declines due to increased generic competition, especially in emerging markets.

Regulatory and Policy Impact

• WHO guidelines now recommend shorter TB regimens, potentially reducing rifampin demand in some cases.
• U.S. CDC updates can influence prescribing patterns, affecting demand and pricing.

Key Takeaways

• NDC 63304-0479 (rifampin 300 mg) is primarily a generic drug with stable, low prices.
• The market is mature, with limited prospects for price increases absent new formulations.
• Competition from rifapentine and other TB agents could further pressure prices.
• Prices are likely to stay within current ranges unless market dynamics shift significantly through regulatory or clinical developments.

FAQs

1. Will rifampin prices increase in the near future?
   Unlikely. The product is off patent and largely commoditized, keeping prices stable.

2. What factors could lead to price declines?
   Increased generic competition, market saturation, or the advent of new, more effective TB therapies.

3. Are there regional differences in pricing?
   Yes. Prices tend to be higher in the U.S. and developed markets, while lower in emerging markets due to local regulations and competition.

4. How does the development of new TB drugs impact rifampin pricing?
   They may reduce demand for rifampin, exerting downward pressure on its price.

5. Is there potential for premium pricing via formulations?
   Only if new delivery systems (e.g., sustained release) or combination therapies are approved and gain acceptance.

---

References

1. World Health Organization. (2022). Global Tuberculosis Report.
2. Agency for Healthcare Research and Quality. (2023). National Drug File – Reference Terminology.
3. GoodRx. (2023). Rifampin Prices.
4. U.S. Food and Drug Administration. (2023). Approved Drug Products.
5. IMS Health. (2022). Pharmaceutical Market Reports.